SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

SpaceX is trending due to widespread anticipation of a potential IPO in 2026, which is igniting significant speculative interest across the broader aerospace sector. Community discussions are heavily focused on identifying "SpaceX IPO plays," with companies like Momentus ($MNTS) gaining traction for its partnership on Falcon 9 missions and a notably low share count, sparking comparisons to past explosive meme stock surges.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending following recent regulatory approvals for its Renergen acquisition, alongside a major firm initiating "Overweight" coverage with a notable price target. The community is actively discussing perceived delays in commercializing key isotopes versus the long-term strategic value of its diverse portfolio spanning nuclear fuel, quantum materials, and helium. Despite recent share price volatility, this blend of strategic acquisitions, analyst validation, and diverse high-demand markets is driving significant investor debate on its future potential.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending following the strategic sale of its Bressner Technology unit, which bolsters its balance sheet and sharpens its focus as a pure-play AI edge computing provider. The community is actively discussing the company's significant undervaluation as an NVIDIA Tier 2 partner, with strong anticipation for an imminent, large "sole-source" military contract for AI-powered situational awareness systems for Army vehicles. This outlook is further supported by recent profitable earnings and an increased sales guidance, fueling expectations for substantial growth in the specialized defense AI sector.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention for its expanding anticoagulation pipeline, highlighted by recent acquisitions and significant progress on its lead candidate, tecarfarin, including manufacturing readiness and a collaboration with Abbott. This "quiet expansion" is sparking community interest, with many anticipating a breakout given its low float and regulatory designations. However, skepticism persists among some regarding the company's financial stability and potential dilution.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kosmos Energy Ltd. (NYSE:KOS) Given Consensus Recommendation of "Hold" by Brokerages

Kosmos Energy Ltd. (NYSE:KOS - Get Free Report) has been given an average recommendation of "Hold" by the eight analysts that are currently covering the stock, MarketBeat.com reports. Two investment...

Kosmos Energy Target of Unusually Large Options Trading (NYSE:KOS)

Kosmos Energy Ltd. (NYSE:KOS - Get Free Report) was the target of unusually large options trading on Friday. Stock traders acquired 4,083 put options on the stock. This is an increase of 55% compared...

Kosmos Energy (LON:KOS) Hits New 1-Year Low - Time to Sell?

Kosmos Energy (LON:KOS) Sets New 1-Year Low - Here's Why...

Kosmos Energy Ltd. $KOS Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC boosted its holdings in shares of Kosmos Energy Ltd. (NYSE:KOS - Free Report) by 333.0% in the second quarter, according to its most recent filing with the Securities and Exchange...

Mizuho Lowers Kosmos Energy (NYSE:KOS) Price Target to $1.50

Mizuho dropped their price objective on Kosmos Energy from $2.00 to $1.50 and set a "neutral" rating for the company in a research note on Friday...

Kosmos Energy (LON:KOS) Sets New 1-Year Low - Time to Sell?

Kosmos Energy (LON:KOS) Reaches New 52-Week Low - Here's What Happened...

Kosmos Energy (NYSE:KOS) Shares Gap Down After Analyst Downgrade

Kosmos Energy (NYSE:KOS) Shares Gap Down on Analyst Downgrade...

Kosmos Energy (NYSE:KOS) Rating Lowered to Accumulate at Johnson Rice

Johnson Rice downgraded Kosmos Energy from a "buy" rating to an "accumulate" rating and set a $3.50 price target for the company. in a report on Friday...

Bank of America Reaffirms Underperform Rating for Kosmos Energy (NYSE:KOS)

Bank of America restated an "underperform" rating and set a $1.00 target price (down previously from $3.40) on shares of Kosmos Energy in a research report on Friday...

Kosmos Energy (LON:KOS) Hits New 12-Month Low - Should You Sell?

Kosmos Energy (LON:KOS) Hits New 1-Year Low - Here's What Happened...

Kosmos Energy Ltd. engages in the exploration, development, and production of oil and gas. The firm's assets include production offshore Ghana, Equatorial Guinea and the U.S. Gulf of Mexico, as well as a gas development offshore Mauritania and Senegal. It also maintains a sustainable exploration program balanced between proven basin infrastructure-led exploration, emerging basins, and frontier basins. The company was founded by Brian F. Maxted on April 23, 2003 and is headquartered in Dallas, TX.

KOS
Kosmos Energy Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KOS News

KOSKosmos Energy Ltd